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Background: Vitamin D deficiency has been linked to several cardiovascular risk factors but information regarding
vitamin D concentrations in familial combined hyperlipidemia (FCHL) is lacking. Our objective was to examine
vitamin D concentrations in patients with FCHL and to study the effects of lipid-lowering therapy.
Methods: We conducted a cross sectional study on 59 patients with FCHL and 48 healthy controls. We analyzed
25-hydroxyvitamin D (25(OH)D) concentrations and their association with lipid parameters, anthropometric measures,
C-reactive protein and homeostasis model assessment (HOMA) index. Twenty-three patients with FCHL were also
included in a longitudinal study conducted to analyze 25-hydroxyvitamin D concentrations before and after
treatment for dyslipidemia.
Results: After adjustment for body mass index and seasonality, patients with FCHL had lower vitamin D
concentrations than controls. Adjusted means (standard error of the mean (S.E.M)) for 25(OH)D according to the
presence or absence of FCHL were 62.8 (3.6) nmol/L for patients with FCHL and 74.8 (4.1) nmol/L for controls
(p = 0.021). In FCHL, hypovitaminosis D was associated with features of atherogenic dyslipidemia. After lipid-lowering
therapy, vitamin D concentrations increased (51.0 ± 31.3 to 58.9 ± 24.6 nmol/L (P = 0.022)). However, changes in 25(OH)
D concentrations did not correlate with changes in other parameters.
Conclusions: Our findings suggest that FCHL is associated with decreased vitamin D concentrations and that
treatment for dyslipidemia improves vitamin D status through an unknown mechanism. Further studies are needed to
replicate these data in larger populations and to elucidate the mechanisms involved in this association.
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There is increasing evidence that vitamin D may have an
effect on cardiovascular outcomes. Many reports have
pointed towards an association of vitamin D deficiency
with the occurrence of fatal and non-fatal cardiovascular
events [1-3] and with several cardiovascular risk factors
such as hypertension, diabetes or dyslipidemia [4-9].
Special attention has been paid to the association of* Correspondence: aperez@santpau.cat
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article, unless otherwise stated.vitamin D deficiency with insulin resistant conditions,
such as obesity or the metabolic syndrome [10-15].
Familial combined hyperlipidemia (FCHL) is a complex
genetic disorder characterized by variable phenotypic ex-
pression and associated with obesity and insulin resistance
[16,17]. It is characterized by hypertriglyceridemia, hyper-
cholesterolemia, reduced high-density lipoprotein choles-
terol (HDL-c), increased apolipoprotein B (apoB) and
predominance of small, dense low-density lipoprotein
(LDL) particles, features that are also present in conditions
of insulin resistance [18,19]. FCHL is the most common
familial form of hyperlipidemia and carries a high risk of
cardiovascular disease.tral Ltd. This is an Open Access article distributed under the terms of the
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low concentrations of vitamin D as occurs with other con-
ditions linked to insulin resistance. To test our hypothesis,
we compared vitamin D concentrations in patients with
FCHL with those from healthy controls. Moreover, we
studied the association of vitamin D concentrations with
anthropometric characteristics, lipoprotein parameters,
C-reactive protein (CRP) and insulin resistance and
analysed the effects of lipid-lowering treatment.
Methods
In a previous study we included 113 patients with FCHL
and 54 normoglycemic and normolipidemic healthy sub-
jects in order to investigate qualitative lipoprotein modi-
fications in FCHL. Patients were recruited between 2007
and 2008 at a tertiary care centre in Spain. Criteria for
FCHL diagnosis were having at least one first-degree
relative with hyperlipidemia and having off-treatment
serum LDL cholesterol (LDL-c) and/or triglyceride levels
above the gender- and age-specific 90th percentiles of
the Spanish reference population [20]. If the patient had
type 2 diabetes, the above criteria and the presence of
LDL-c levels > 4.14 nmol/L were mandatory. The pres-
ence of secondary causes of dyslipidemia was an exclu-
sion criteria. Controls were recruited within hospital
employees and their relatives and were included in the
study if they had not been previously diagnosed with
disturbances of lipid or glucose metabolism and had
glucose concentrations < 5,6 mmo/L, LDL-c concen-
trations < 4,14 mmol/L and triglyceride concentra-
tions < 2,25 mmol/L. For the present study, we selected
59 patients with FCHL and 48 healthy controls for whom
frozen serum samples were available in order to determine
25-hydroxyvitamin D (25(OH)D) concentrations. All pa-
tients and controls were included in a transversal study.
Twenty-three of the 59 patients with FCHL were also in-
cluded in a longitudinal study and vitamin D concentra-
tions were studied before and after treatment for their
dyslipidemia for a minimum of 2 months. All subjects
were Caucasian and none were taking vitamin D supple-
ments. The investigation conforms to the principles
outlined in the Declaration of Helsinki and was approved
by the hospital ethics committee. All patients gave written
informed consent prior to participation.
Blood specimens were obtained after overnight fasting.
The basic lipid profile was obtained using fresh blood
samples. All other analyses were performed using ethyl-
enediaminetetraacetic acid-plasma samples frozen at
-80ºC. To minimize inter-assay variability, samples from
the same subject were analyzed in the same batch.
The lipid profile included total cholesterol, triglycerides,
very low-density lipoprotein cholesterol (VLDL-c), LDL-c,
HDL-c, apoB, and non-esterified fatty acids (NEFA). Total
cholesterol and triglycerides were measured by commerciallyavailable enzymatic methods, and HDLc was measured by a
direct method. LDLc was calculated using Friedewald’s
formula when triglycerides did not exceed 300 mg/dl
(3.45 mmol/liter) [21]. Otherwise, ultracentrifugation
was performed, and LDLc was estimated in the infra-
natant after separating the fraction with a density less
than 1.006. kg/liter, according NCEP-ATPIII recom-
mendations [22]. VLDLc was calculated by substrac-
tion. All reagents were from Roche Diagnostics GmbH,
Basel, Switzerland, except for NEFA (Wako Chemicals,
Neuss, Germany) and all tests were performed in a
Hitachi 917 auto analyzer. LDL size was determined by
nondenaturing polyacrylamide gradient (2% to 16%)
gel electrophoresis, as previously described [23].
CRP was measured by a highly sensitive commercial
method (hsCRP, Roche Diagnostics) in a Hitachi 917
auto analyzer.
In subjects with FCHL, serum insulin concentrations
were measured by an automated, solid-phase, two-site
chemiluminescent immunometric assay (Immulite 2000,
Diagnostic Products Corp., Los Angeles, California, USA),
with 8% cross-reactivity with proinsulin and a total analyt-
ical imprecision less than 7.5% for values between 55 and
2100 pmol/L (7.7 and 291 mIU/mL). The homeostasis
model assessment (HOMA) index was calculated as
(glucose (mmol/L) · insulinemia (μUI/mL))/22.5 and
insulin resistance was defined as HOMA concentra-
tions > 3.29, based on the 90th percentile of the Spanish
population [24,25].
Serum 25(OH)D concentrations were determined using
a commercial enzyme immunoassay (Immunodiagnostic
Systems Ltd (IDS), Boldon, United Kingdom). Both intra-
and inter-assay coefficients of variation (CVs) for serum
25(OH)D were < 6.8% and < 8.8%, respectively, for mean
concentrations between 38 and 164 nmol/L. Analytical
sensitivity was 5 nmol/L. Previous reports show that
25-hydroxyvitamin D is extremely stable in plasma and
that serum degradation of vitamin D has not been
proven after 10 years stored in a frozen state [26]. 25(OH)D
concentrations were defined as sufficient (>80 nmol/L) or
hypovitaminosis D (≤80 nmol/L) based on previous studies
regarding the effects of vitamin D on parathyroid hormone,
calcium absorption, and bone mineral density [27].
Data were analyzed using the SPSS 18.0 statistical
package (SPSS Inc). Normality of data distribution was
evaluated using Kolmogorov-Smirnov in the transversal
analysis and Shapiro-Wilk test in the longitudinal ana-
lysis. The relationship between qualitative variables was
assessed using Chi-square test and quantitative variables
were analyzed by means of Pearson’s or Spearman’s cor-
relation coefficient. Differences between groups were
evaluated by T-test, Mann–Whitney test and analysis
of covariance (ANCOVA). For the longitudinal study
Mann–Whitney test, paired T-test, Wilcoxon test and
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The level of statistical significance was set at p < 0.05.
Results
Cross-sectional study
Table 1 shows the clinical characteristics of patients with
FCHL and control subjects. Among subjects with FCHL,
5 patients (8.5%) had type 2 diabetes and 21 patients
(35.6%) had hypertension. Seventeen patients (28.8%) were
taking statins and 6 (10.2%) were taking fenofibrate.
As expected, all lipid parameters were higher in pa-
tients with FCHL, except for HDL-c, which was lower. A
trend towards lower 25(OH)D concentrations in patients
with FCHL was observed. Results from the ANCOVA
performed to detect differences in 25(OH)D concentra-
tions between patients and controls after adjusting for
seasonality and body mass index (BMI), showed that
seasonality (p = 0.007) and the presence or absence of
FCHL (p = 0.021) were significant predictors of 25(OH)D
concentrations, whereas BMI did not influence them. Ad-
justed means (standard error of the mean (S.E.M)) for 25
(OH)D, according to the presence/absence of FCHL and ad-
justed for seasonality and BMI, were 62.8 (3.6) nmol/L for
patients with FCHL and 74.8 (4.1) nmol/L for controls. Cor-
relation analysis did not show any association between 25
(OH)D concentrations and BMI, waist, age, lipid parametersTable 1 Clinical and biochemical characteristics of
patients with FCHL and control subjects
Cases (n = 59) Controls (n = 48) P
Age (years) 50.2 ± 11.6 46.5 ± 17.2 0.210
Sex (% men) 57.6 62.5 0.609
BMI (Kg/m2) 27.9 ± 4.1 25.4 ± 4.1 0.005
Waist (cm) 0.026
- Men 97.7 ± 9 91.79 ± 12.1
- Women 92.7 ± 12.4 88.8 ± 11.8
Glucose (mmol/L) 5.3 ± 0.6 4.9 ± 0.73 0.020
HbA1c (%) 5.6 ± 0.5 5.4 ± 0.6 0.135
Total cholesterol (mmol/L) 6.7 ± 1.6 4.8 ± 0.8 0.000
Triglycerides (mmol/L) 2.3 (1.1-15.8) 0.7 (0.3-2.1) 0.000
LDL-c (mmol/L) 4.1 ± 1.3 2.8 ± 0.7 0.000
HDL-c (mmol/L) 1.2 ± 0.4 1.6 ± 0.4 0.000
VLDL-c (mmol/L) 1.0 (0.5-7.6) 0.4 (0.1-1.2) 0.000
NEFA (mmol/L) 0.7 (0.2-4.3) 0.4 (0.1-1.1) 0.000
ApoB (g/L) 1.3 ± 0.3 0.8 ± 0.2 0.000
CRP (mg/L) 1.6 (0.2-21.5) 1.0 (0.2-15.0) 0.133
25(OH)D (nmol/L) 58.9 ± 24.5 69.1 ± 30.0 0.057
P values according to T-test and Mann–Whitney test.
FCHL: Familial combined hyperlipidemia, BMI: body mass index, HbA1c:
glicated haemoglobin, LDL-c: low-density lipoprotein cholesterol, HDL-c: high-density
lipoprotein cholesterol, VLDL-c: very low-density lipoprotein cholesterol, NEFA:
non-esterified fatty acids, ApoB: apolipoprotein B, CRP: C-reactive protein,
25(OH)D: 25-hydroxyvitamin D.or CRP in controls. However, in subjects with FCHL,
calcidiol concentrations correlated with LDL-c (r 0.257;
p = 0.049) and triglyceride concentrations (r −0.265;
p = 0.042).
Forty- six patients with FCHL (78.8%) presented hypovi-
taminosis D. Patients with hypovitaminosis D had higher
triglyceride and NEFA concentrations and lower LDL-c
and HDL-c concentrations than patients with normal
25(OH)D concentrations (Table 2). Differences in triglycer-
ide and NEFA concentrations remained significant after ad-
justment for seasonality and BMI. Furthermore, patients
with triglyceride concentrations > 2.25 nmol/L (200 mg/dL)
had lower 25(OH)D concentrations than patients with tri-
glyceride < 2.25 nmol/L (50.63 ± 21.3 vs. 67.49 ± 25 nmol/L;
p = 0.007). No differences in 25(OH)D concentrations
were found between patients with and without lipid-
lowering therapy or between patients with or without
insulin resistance.Longitudinal study
Twenty-three patients were included in the longitudinal
study. Their mean age was 50.13 ± 10.2 years and 65.2%
were men. Data are reported before and after 2.5 (1.9-12.9)
months of treatment for their dyslipidemia. Three patients
were treated with diet alone, 11 with statins, 5 with fibrates,Table 2 Clinical and biochemical characteristics of






Age (years) 51.7 ± 10.3 44.9 ± 14.5 0.061
BMI (Kg/m2) 28.2 ± 4.0 26.8 ± 4.0 0.289
Waist (cm) 96.2 ± 10.1 93.3 ± 12.8 0.412
HbA1c (%) 5.6 ± 0.5 5.6 ± 0.4 0.838
HOMA 2.7 ± 2.4 1.8 ± 0.9 0.838
Total cholesterol (mmol/L) 6.6 ± 1.6 7.1 ± 1.3 0.335
Triglycerides (mmol/L) 2.5 (1.1-15.8) 2.0 (1.2-3.1) 0.041
LDL-c (mmol/L) 3.9 ± 1.2 4.8 ± 1.3 0.025
HDL-c (mmol/L) 1.1 ± 0.4 1.3 ± 0.3 0.051
VLDL-c (mmol/L) 1.1 (0.5-7.6) 0.9 (0.6-1.3) 0.079
NEFA (mmol/L) 0.7 (0.3-4.3) 0.5 (0.2-1.1) 0.015
ApoB (g/L) 1.3 ± 0.3 1.4 ± 0.3 0.116
LDL size (nm) 25.4 ± 0.7 25.7 ± 0.4 0.184
CRP (mg/L) 1.6 (0.3-21.1) 1.5 (0.2-21.5) 0.901
25(OH)D (nmol/L) 48.2 ± 14.3 96.9 ± 11.7 0.000
P values according to T-test and Mann–Whitney test.
FCHL: Familial combined hyperlipidemia, BMI: body mass index, HbA1c:
glicated haemoglobin, HOMA: homeostasis model assessment, LDL-c: low-density
lipoprotein cholesterol, HDL-c: high-density lipoprotein cholesterol, VLDL-c: very
low-density lipoprotein cholesterol, NEFA: non-esterified fatty acids, ApoB:
apolipoprotein B, CRP: C-reactive protein, 25(OH)D: 25-hydroxyvitamin D.
Vitamin D deficiency = 25(OH)D ≤ 80 nmol/L.
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ezetimibe.
As expected, all lipid parameters improved after treat-
ment. No significant changes were seen regarding anthropo-
metric parameters and CRP levels (Table 3). However, 25
(OH)D concentrations increased from 51.0 ± 31.3 to 58.9 ±
24.6 nmol/L (p = 0.022). The increase in 25(OH)D concen-
trations was higher in patients treated with a statin
alone or in combination (7.5 (−10.6-46.5) vs. 1.45 (−17-7.1;
p = 0.039). No differences were found between patients
who received or not a fibrate. Changes in 25(OH)D con-
centrations did not correlate with changes in anthropomet-
ric measures, HOMA index, lipid parameters or CRP.
We analysed the time of the year when blood samples
were obtained in order to detect possible influences of
sun exposure on the changes observed in 25(OH)D con-
centrations. We considered two periods of sun exposure:
a period of reduced sun exposure (November to April)
and a period of maximum sun exposure (May to October)
and we observed that 20 patients had both determina-
tions, before and after treatment, during the same period
of sun exposure. Only 3 patients had their first blood sam-
ple (off-treatment) taken during the period of less sun ex-
posure and the second blood sample (after treatment)
during the period of more sun exposure.
Discussion
The main finding in the present study is that patients
with FCHL had lower 25(OH)D concentrations that areTable 3 Characteristics of patients with FCHL included in
the longitudinal study before and after treatment for
their dyslipidemia
Off- treatment With treatment P
25(OH)D (nmol/L) 51.0 ± 31.3 58.9 ± 24.6 0.022
BMI (Kg/m2) 26.6 ± 2.6 26.6 ±2.6 0.778
Waist (cm) 92.7 ± 9.2 93.1 ± 8.8 0.518
HOMA 2.0 ± 1.1 2.2 ± 1.4 0.535
Total cholesterol (mmol/L) 7.4 (5.1-16.1) 5.1 (3.8-8.9) 0.000
Triglycerides (mmol/L) 2.8 (1.2-10.7) 1.9 (0.8-3.8) 0.000
LDL-c (mmol/L) 4.3 (1.4-7.8) 3.0 (2.0-5.8) 0.007
HDL-c (mmol/L) 1.2 ± 0.4 1.3 ± 0.3 0.000
VLDL-c (mmol/L) 1.3 (0.6-8.6) 0.9 (0.4-3.3) 0.000
NEFA (mmol/L) 0.6 (0.3-1.6) 0.6 (0.3-1.4) 0.313
ApoB (g/L) 1.4 ± 0.3 1.0 ± 0.2 0.000
LDLsize (nm) 25.3 (23.2-26.2) 25.7 (24.8-26.5) 0.058
CRP (mg/L) 2.0 (0.1-21.1) 1.3 (0.3-12.2) 0.823
P values according to paired T-test and Wilcoxon test.
FCHL: Familial combined hyperlipidemia, 25(OH)D: 25-hydroxyvitamin D, BMI:
body mass index, HOMA: homeostasis model assessment, LDL-c: low-density
lipoprotein cholesterol, HDL-c: high-density lipoprotein cholesterol, VLDL-c:
very low-density lipoprotein cholesterol, LDL: low-density lipoprotein, NEFA:
non-esterified fatty acids, ApoB: apolipoprotein B, CRP: C-reactive protein.related to lipid alterations and that treatment for dyslip-
idemia in our routine clinical practice was associated
with an increase in 25(OH)D concentrations. These find-
ings are novel and suggest that hypovitaminosis D is paral-
lel to lipid alterations characteristic of FCHL.
In recent years, several reports have pointed out a pos-
sible association between vitamin D concentrations and
dyslipidemia. In 1989, Wilczek et al. [28] found that het-
erozygotes with familial hypercholesterolemia suffered
from vitamin D deficiency. Later on, associations of 25
(OH)D with the different lipid parameters have been
found in a wide range of populations. Melamed et al.
[29] found an association between 25(OH)D and choles-
terol concentrations in US participants of the National
Health And Examination Survey (NHANES). Moreover,
Lu et al. [30] and Lee et al. [14] found associations be-
tween 25(OH)D and HDL-c and triglyceride concentra-
tions in Chinese and European populations, respectively.
The widest study assessing the association between vita-
min D and lipids included 108711 patients from a pri-
vate clinical database in US; patients with optimal 25
(OH)D concentrations had lower LDL-c and triglycer-
ides and higher HDL-c concentrations than patients
with suboptimal 25(OH)D concentrations [31]. In obese
subjects, atherogenic dyslipidemia has been associated
with hypovitaminosis D [32]. Finally, a meta-analysis of
22 cross-sectional studies concludes there is an associ-
ation of vitamin D deficiency with an unfavourable lipid
profile characterized by low HDL-c and high triglyceride
concentrations [9]. Results from this meta-analysis, how-
ever, point out that not all studies adjusted their findings
for possible confounders such as gender, age or BMI.
Furthermore, they show discordant findings regarding
the association of 25(OH)D concentrations with total
cholesterol or LDL-c. Our study adds knowledge to the
relation of vitamin D with lipid disorders by showing
that FCHL, an inherited disease closely linked to the
metabolic syndrome, is also associated with decreased
25(OH)D concentrations. Furthermore, and in accord-
ance with previous studies, our patients with FCHL and
vitamin D deficiency presented higher triglyceride and
NEFA concentrations and lower LDL-c and HDL-c con-
centrations. Most of these associations persist after
adjusting for BMI, suggesting a direct relationship be-
tween 25(OH)D and the lipid profile characteristic of
atherogenic dyslipidemia.
Several authors have shown that statin use may be as-
sociated with beneficial effects on bone fracture [33]. Al-
though the underlying mechanism for this association is
unknown, the possibility that statins increase vitamin D
concentrations cannot be ruled out. In fact, although re-
sults are heterogeneous, several studies have found a
positive effect of statin use on vitamin D deficiency and
some authors suggest that this effect might be through
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their intrinsic effect on serum lipids [34-38]. Information
regarding the effect of lipid-lowering drugs other than
statins is scarce but ezetimibe and fibrates could also
have an effect [39,40]. In our study, treatment for dyslip-
idemia was accompanied by an increase in 25(OH)D
concentrations of 7.86 nmol/L. As our patients were
treated in a clinical practice setting, the type and dose
of lipid lowering medications was heterogeneous; most
patients received statins, but a considerable number
were also treated fibrates in monotherapy or combined
with statins. BMI did not change during the longitu-
dinal study and it is interesting to note that changes in
lipid parameters did not correlate with changes in 25
(OH)D concentrations, suggesting that the effect of
lipid-lowering therapy on vitamin D metabolism may
be through a lipid independent pathway. In fact, although
our results should be treated with caution due to the small
number of subjects included, we have found that patients
prescribed statins had greater increases in vitamin D con-
centrations than patients not taking statins. Thus, a plei-
tropic effect of lipid-lowering drugs, specially statins, on
vitamin D concentrations cannot be ruled out.
The main strength of our work is the adjustment for
potential confounders such as BMI and seasonality,
when considering differences in vitamin D concentra-
tions in cross-sectional analysis. Furthermore, patient se-
lection excluded subjects taking vitamin D derivatives,
and, as all patients were Caucasian, a possible effect of
different ethnicities on vitamin D metabolism was elimi-
nated. In the longitudinal study, as most determinations
were performed at the same sunlight period, the possible
effect of changes in seasonality was minimized. The
main limitation of our work is patient number and the
fact that the cross-sectional design of the analysis does
not enable to draw causative relations between FCHL
and vitamin D. However, the fact that treatment for dys-
lipidemia is associated with an increase in 25(OH)D
concentrations, independently of lipid changes suggests
that the association of FCHL with vitamin D is complex
and not only driven by lipid parameters. Reference group
selection included patients with overweight or with in-
creased CRP; however, this should not be taken as a
limitation as, if more strict selection criteria were applied,
probably differences found would have been magnified. Fi-
nally, we cannot exclude that changes in lifestyle habits
that accompany treatment initiation for dyslipidaemia,
could partly account for vitamin D changes, so further
studies are needed to confirm our findings.
Conclusions
The main conclusion of our work is that FCHL is associ-
ated with decreased vitamin D concentrations that are re-
lated to features characteristic of atherogenic dyslipidemia.Moreover, treatment for dyslipidemia improves vitamin D
status through an unknown mechanism. As vitamin D de-
ficiency seems to play an important role in cardiovascular
health, the decreased vitamin D concentrations found in
patients with FCHL may contribute to the development of
atherosclerosis in patients with this primary hyperlipid-
emia. Future studies are needed to replicate these data in
larger populations and to elucidate the mechanisms that
are involved in this association.
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